IPP Bureau
WHO report reveals stark global inequities in genomic research
By IPP Bureau - December 27, 2025
EU nod to Wayrilz as breakthrough treatment for hard-to-treat ITP
By IPP Bureau - December 27, 2025
Wayrilz represents a new approach to ITP by targeting the disease at its root through multi-immune modulation
Chugai’s Tecentriq gets green light in Japan for hard-to-treat Thymic Carcinoma
By IPP Bureau - December 27, 2025
The drug had previously received orphan drug designation for this rare cancer on March 31, 2025
Zeon Corporation to acquire Ushio’s microfluidics biz
By IPP Bureau - December 27, 2025
Ushio, a leader in advanced optical technologies, brings a strong track record and proprietary Photobonding technology
Symbiosis rolls out first 10,000 vial batch at Stirling Facility
By IPP Bureau - December 27, 2025
This production milestone positions Symbiosis at the forefront of meeting rising global demand for life-saving medicines
IRLAB launches Phase Ib Trial of IRL757 for Parkinson’s patients with Apathy
By IPP Bureau - December 27, 2025
The multicenter study will enroll 75 patients across 16 sites in Germany, Bulgaria, Poland, and Spain
Amneal and mAbxience score FDA green light for two Denosumab biosimilars
By IPP Bureau - December 27, 2025
Edwards Lifesciences’ SAPIEN M3 becomes first FDA-approved transseptal mitral valve replacement
By IPP Bureau - December 27, 2025
The SAPIEN M3 transcatheter mitral valve replacement (TMVR) system is designed for patients with symptomatic moderate-to-severe or severe MR
Nona Biosciences expands platform to accelerate early clinical trials
By IPP Bureau - December 27, 2025
Nona aims to help global biopharmaceutical companies fast-track clinical trial initiation without compromising scientific rigor or quality standards
AB Science secures US patent for Masitinib in sickle cell disease till 2040
By IPP Bureau - December 27, 2025
Masitinib targets mast cells, which play a critical role in severe forms of SCD and its complications, including vaso-occlusive crises, acute chest syndrome, and pain
FDA okays AQVESME as first treatment for anemia in alpha- & beta-thalassemia
By IPP Bureau - December 27, 2025
The approval makes AQVESME the only FDA-approved therapy for anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia
Strides Pharma Inc's Chestnut Ridge facility gets 4 observations from USFDA
By IPP Bureau - December 26, 2025
These observations are procedural in nature and the company does not anticipate any impact on supply of its commercial products
Dr Kaustav Talapatra named ASTRO’s International Ambassador from India
By IPP Bureau - December 26, 2025
Sanofi to acquire Dynavax in $2.2 billion deal, bolstering adult vaccine portfolio
By IPP Bureau - December 26, 2025
The move strengthens Sanofi’s presence in adult immunization by combining Dynavax’s innovative vaccines with Sanofi’s global scale and development capabilities
